Patients with pemphigus vulgaris (PV) have circulating anti-desmoglein (Dsg) 3 immunoglobulin G (IgG) autoantibodies that induce blister formation. We developed an in vitro quantitative assay to evaluate the pathogenic strength of anti-Dsg3 IgG autoantibodies in blister formation. To obtain intercellular adhesion mediated dominantly by Dsg3, we used primary cultured normal human keratinocytes expressing low level of Dsg2 in the presence of exfoliative toxin A that specifically digests Dsg1. After incubation with various antibodies, monolayers released by dispase were subjected to mechanical stress by pipetting, and the number of cell fragments were counted. When anti-Dsg3 monoclonal antibodies (mAb) obtained from pemphigus model mice were tested, pathogenic AK23 mAb yielded significantly higher number of cell fragments than AK7 or AK20 non-pathogenic mAb. Dissociation scores, defined with AK23 mAb as the positive control, were significantly higher with active stage PV sera (n=10, 77.4+/-21.4) than controls (n=11, 16.0+/-9.6; p=0.003). When pair sera obtained from 6 PV patients in active stage and in remission were compared, the dissociation scores reflected well the disease activity as those in active stage were four to 17 times higher than those in remission. When sera from different patients showing similar ELISA scores but different clinical severity were tested (n=6), the dissociation scores with sera from severe disease activity were significantly higher than those with sera in remission. These findings indicate that this dissociation assay will provide a simple and objective biological method to measure the pathogenic strength of pemphigus autoantibodies.

The clinical phenotype at each stage is defined by the anti-Dsg antibody profile in the serum of these pemphigus patients showing mixed features of PF and PV. In addition, ELISA using recombinant baculoproteins was particularly useful in distinguishing PF and PV.

amino acid possessing similar structure to leucine but shorter sidechain. The mutation from leucine to valine is pathogenic despite the fact that it is a substitution to a similar amino acid attesting the conservation and functional importance of this protein motif. In K14, a type 1 keratin expressed in the basal keratinocytes, there was one report with a mutation at residue 7 of HIM (L122F), resulting in a milder disease phenotype of epidermolysis bullosa simplex (Yamanishi et al, 1994). Phenylalanine is a hydrophobic amino acid similar to leucine but having a larger side chain. This case further supports the idea that the mutation at HIM residue 7 of type I keratin is pathogenic, even if the mutation is a substitution to a similar, hydrophobic residue. More cases should be accumulated to clarify the genotype-phenotype relationship of the mutation at this residue.